Director Johannes Gerardus Christiaan Petrus Schikan reported the sale of 7,100 shares of Pharvaris N.V. (PHVS +2.06%) in two open-market transactions, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 7,100 |
| Transaction value | ~$213,000 |
| Post-transaction shares (direct) | 388,067 |
| Post-transaction value (direct ownership) | ~$10.59 million |
Transaction value based on SEC Form 4 weighted average price ($30.05); post-transaction value based on April 23, 2026 market close ($27.29).
Key questions
- How material was this transaction relative to Schikan's total position?
The 7,100 shares sold accounted for 1.80% of his direct holdings, reflecting a modest reduction in stake and leaving a remaining direct position of 388,067 shares. - Were any indirect holdings or derivative securities involved?
No shares were reported as indirectly held, and there were no derivative (option) transactions disclosed in this filing. - What was the context for the sale and does it indicate any change in intent?
The transaction was executed under a pre-scheduled Rule 10b5-1 trading plan, signaling planned liquidity management rather than a shift in Schikan's outlook or involvement with the company. - How does the transaction align with capacity and recent history?
This is Schikan's only sale in the past year, with the amount reflecting a small percentage of his available shares and not indicating any capacity-driven or escalating pattern.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $1.87 billion |
| Employees | 108 |
| Net income (TTM) | -$198.12 million |
| 1-year price change | 65.42% |
* 1-year price change calculated as of April 28, 2026.
Company snapshot
- PHVS develops and advances clinical-stage therapies targeting hereditary angioedema (HAE), including PHA121 (oral B2-receptor antagonist), PHVS416 (on-demand soft capsule), and PHVS719 (prophylactic extended-release tablet).
- Pharvaris operates a research-driven business model focused on the development and eventual commercialization of novel therapeutics for rare diseases, with future revenue expected from successful product approvals and market launches.
- The company targets patients suffering from hereditary angioedema, with healthcare providers, specialty clinics, and rare disease treatment centers as primary customers.
Pharvaris N.V. is a clinical-stage biopharmaceutical company specializing in innovative oral therapies for rare diseases, with a primary focus on hereditary angioedema. The company leverages a pipeline of differentiated drug candidates in various clinical stages, aiming to address significant unmet medical needs.
With operations in Europe and the United States, Pharvaris seeks to establish a competitive edge through proprietary small molecule drug design and a targeted approach to rare disease markets.
What this transaction means for investors
This sale doesn't tell investors much. Director Schikan trimmed 7,100 shares — about 1.80% of his direct holdings — across April 22 and 23 under a Rule 10b5-1 plan, leaving him with 388,067 shares directly held. A small scheduled trim by a director who still owns nearly four hundred thousand shares isn't the kind of move that signals anything about his view on the stock. If you're following Pharvaris, the more useful things to watch this year aren't insider trims. The company expects topline data from CHAPTER-3, its pivotal Phase 3 study of deucrictibant XR for prophylactic hereditary angioedema treatment, in the third quarter of 2026. It also plans to submit a U.S. NDA for deucrictibant IR for on-demand HAE treatment in the first half of 2026. A clinical-stage biotech with no revenue lives or dies on regulatory milestones — those two catalysts will move the stock far more than a director's scheduled trim.
